https://allsci.com/news/licensing-and-partnerships/lnp-chemistry-car-platform-create-medicines/ AllScien 2026-07-31T16:53:13.305621Z CREATE Medicines licenses Monash's targeted LNP chemistry to expand in vivo CAR platform https://allsci.com/news/licensing-and-partnerships/senaparib-license-agreement-impact-therapeutics/ AllScien 2026-07-31T16:43:12.072980Z Pharmanovia takes on Impact's senaparib outside US, China for EUR 423.5m https://allsci.com/news/clinical-trials/ziltivekimab-zeus-trial-failure-novo-nordisks/ AllScien 2026-07-31T16:18:39.462972Z Novo's ziltivekimab misses cardiovascular endpoint despite biomarker success https://allsci.com/news/first-in-human-trials/car-t-therapy-autoimmune-create-medicines-gains/ AllScien 2026-07-31T16:04:56.250820Z CREATE clears Australian ethics review for first-in-human in vivo CAR-T study https://allsci.com/news/clinical-trials/scancell-neuphoria-merger-merges-with-nasdaq/ AllScien 2026-07-31T15:25:48.833144Z Scancell taps Nasdaq reverse merger to fund Phase III melanoma program https://allsci.com/news/licensing-and-partnerships/in-vivo-car-t-therapies-jj-secures-option-to/ AllScien 2026-07-31T13:01:13.242265Z J&J secures option to acquire Sail in USD 3.5 billion in vivo CAR-T alliance https://allsci.com/news/research/intestinal-organoid-platform-intero-biosystems/ AllScien 2026-07-31T13:00:11.183231Z Intero Biosystems's intestinal organoid platform backed by SBIR https://allsci.com/news/approvals/long-acting-insulin-analog-china-hengrui-wins/ AllScien 2026-07-31T12:56:19.384297Z Hengrui wins China approval for first domestically developed basal insulin analog https://allsci.com/news/discovery/ai-drug-discovery-benchmark-insilico-medicine/ AllScien 2026-07-31T12:40:57.041037Z Insilico launches AI benchmarking platform for drug discovery models https://allsci.com/news/regulatory/rp1-melanoma-fda-approval-advisory-committee/ AllScien 2026-07-31T12:34:55.219628Z Replimune overcomes skeptical FDA briefing as panel backs RP1 in 10-3 vote https://allsci.com/news/regulatory/fda-fast-track-mesothelioma-insilicos-ai-designed/ AllScien 2026-07-31T12:34:50.132549Z Insilico's AI-designed TEAD inhibitor secures FDA fast track for mesothelioma https://allsci.com/news/regulatory/ocu410-rmat-designation-fda-grants-regenerative/ AllScien 2026-07-31T12:34:41.851668Z Ocugen's gene therapy gets FDA RMAT for geographic atrophy https://allsci.com/news/regulatory/rybrevant-faspro-fda-approval-jjs-gains-priority/ AllScien 2026-07-31T12:34:25.287116Z J&J's Rybrevant Faspro gains priority review for head and neck cancer after immunotherapy failure https://allsci.com/news/research/breast-cancer-detection-plasma-proteomics/ AllScien 2026-07-31T12:34:18.288948Z Astrin Bio and University of Minnesota report plasma proteomics classifier for early-stage breast cancer detection https://allsci.com/news/licensing-and-partnerships/kaigene-kg006-taisho-deal-maps-final-territory/ AllScien 2026-07-31T12:34:09.256054Z Kaigene licenses Japan rights to FcRn inhibitor KG006 to Taisho in deal worth up to USD 378m https://allsci.com/news/ipo-public-listing/apnimed-ipo-sleep-apnea-raises-usd-192m-in-ahead/ AllScien 2026-07-31T12:33:59.510166Z Apnimed raises USD 192m in IPO ahead of Q1 2027 sleep apnea drug decision https://allsci.com/news/licensing-and-partnerships/rna-delivery-technology-mirecule-partners-with/ AllScien 2026-07-31T12:33:50.968773Z miRecule partners with EMS subsidiary to expand RNA delivery beyond the liver https://allsci.com/news/approvals/datroway-tnbc-approval-eu-approves-as-first-trop2/ AllScien 2026-07-31T12:33:31.629371Z EU approves Datroway as first TROP2 ADC with OS benefit in first-line metastatic TNBC https://allsci.com/news/regulatory-pathways/selinexor-ruxolitinib-myelofibrosis-karyopharm/ AllScien 2026-07-31T12:29:21.870544Z Karyopharm to file myelofibrosis sNDA after FDA backs SVR35 surrogate endpoint https://allsci.com/news/regulatory/fda-rmat-designation-parkinsons-grants-aspen-for/ AllScien 2026-07-31T12:19:16.153463Z FDA grants Aspen RMAT designation for cell therapy in Parkinson's disease https://allsci.com/news/licensing-and-partnerships/gsk-relation-collaboration-ai-drug-discovery/ AllScien 2026-07-30T18:52:27.739148Z Relation expands GSK collaboration to USD 110m with MORGAN foundation model for target discovery https://allsci.com/news/regulatory/enzomenib-orphan-drug-designation-fda-grants/ AllScien 2026-07-30T16:38:27.895802Z Sumitomo's enzomenib gets FDA orphan drug designation for ALL https://allsci.com/news/regulatory/ritlecitinib-vitiligo-pfizers-advances-to-become/ AllScien 2026-07-30T16:35:55.700950Z Pfizer's Litfulo succeeds in Phase III vitiligo trials, setting up rivalry with Rinvoq https://allsci.com/news/clinical-trials/cnd319-phase-i-trial-candid-initiates-of-dual/ AllScien 2026-07-30T16:18:51.760415Z Candid's trispecific CND319 enters first-in-human testing under UCB https://allsci.com/news/research/car-t-cell-toxicity-prediction-germline-variants/ AllScien 2026-07-30T16:18:34.200464Z Kite-backed study identifies inherited genetic predictors of CAR-T toxicity and expansion https://allsci.com/news/public-offerings/inovio-fda-decision-ino-3107-raises-usd-20m-ahead/ AllScien 2026-07-30T16:17:05.503962Z Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 https://allsci.com/news/business/jj-firefly-bio-acquisition-kras-johnson-johnson/ AllScien 2026-07-30T16:16:55.457779Z J&J completes USD 1b Firefly acquisition to add pan-KRAS degrader capabilities https://allsci.com/news/pipe-financing/btk-inhibitor-acquisition-processa-acquires/ AllScien 2026-07-30T16:13:05.150734Z Processa acquires CNS-penetrant BTK inhibitor with USD 200m financing for three Phase II programs https://allsci.com/news/regulatory/deramiocel-fda-dmd-cardiomyopathy-advisory/ AllScien 2026-07-30T15:57:51.962487Z FDA advisory committee votes against Capricor's deramiocel effectiveness for DMD cardiomyopathy https://allsci.com/news/first-in-human-trials/oral-amylin-analog-verdiva-advances-first-with/ AllScien 2026-07-30T14:57:10.129253Z Verdiva advances oral amylin strategy with first-in-human study of VRB-103 https://allsci.com/news/regulatory/fda-clearance-iks04-adc-clears-iksudas-for-phase/ AllScien 2026-07-30T14:52:44.547134Z FDA clears Iksuda's CA242-targeted ADC for Phase I study in GI cancers https://allsci.com/news/clinical-trials/biogen-lupus-trials-2027-accelerates-and/ AllScien 2026-07-30T14:22:03.446931Z Biogen Q2'26: Lupus, AMR and Dravet catalysts take center stage https://allsci.com/news/research/mammarenavirus-inhibitor-development-scripps/ AllScien 2026-07-30T13:52:38.664251Z Scripps advances dual-target mammarenavirus antivirals with NIAID funding https://allsci.com/news/clinical-trials/caldera-taps-reverse-merger-to-advance-tl1a-x-il-23-bispecific/ AllScien 2026-07-29T17:17:16.972374Z Caldera taps reverse merger to advance TL1A × IL-23 bispecific https://allsci.com/news/venture-financing/adjuvia-raises-usd-8m-for-preclinical-stage-mitochondrial-therapy/ AllScien 2026-07-29T17:04:21.481730Z Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy